BioNTech

BioNTech’s $16.8 Billion Question: Can Oncology Data Justify the Wait?

BioNTech转型关键期：专利诉讼阴云与肿瘤管线曙光交织，8月4日二季报成多空分水岭

Brett Shapiro -

BioNTech四面楚歌：专利诉讼与肿瘤转型的双重博弈，8月财报成关键变量

kashif hafeez -

BioNTech肿瘤转型遭遇“技术性僵局”：ARK清仓与百日均线拉锯下的8月4日关键节点

Brett Shapiro -

BioNTech Faces a Legal Storm as Q1 Revenue Misses and a $1 Billion Buyback Awaits Judgment Day

BioNTech腹背受敌：8月4日二季报能否化解专利围城与转型困局？

BioNTech二季报倒计时：肿瘤转型成效将迎市场“大考”

kashif hafeez -

BioNTech’s HIV Vaccine Moves to Clinic Amid Patent Fights and a Shrinking COVID Business

BioNTech专利诉讼四面来袭，肿瘤管线六项数据成破局关键

kashif hafeez -

BioNTech多重博弈：Moderna觊觎工厂、168亿现金护盘、肿瘤数据成最后定音

Brett Shapiro -

BioNTech的”双重试炼”：从新冠捍卫者到肿瘤帝国，分步验证策略下的股价窄幅博弈

Brett Shapiro -

BioNTech悬崖边的豪赌：关厂减支、两创始交棒、肿瘤管线七轮数据定命运

kashif hafeez -

BioNTech Nears a Crossroads: Factory Closures, Founder Exits, and a Cancer-Pipeline Bet Are All Converging

kashif hafeez -

BioNTech转型迷雾：降目标、迎换帅、押注15项肿瘤临床，市场等待8月财报定方向

BioNTech’s Pivotal Week: A Legal Win, Factory Talks with Moderna, and a Looming Leadership Void

angelina -
1...345...15Page 4 of 15